Veterinary Practice M&A Multiples Report 2026: Valuation Benchmarks by Size and Segment

Last updated: June 29, 2026

Scope and differentiation from the sister guide

This report is a strict M&A transaction-multiple benchmark for closed US veterinary practice deals across the 2019 through Q1 2026 window. It is a companion to, not a replacement for, the owner-operator SDE-basis valuation walk-through at /guides/veterinary-business-valuation/. Readers looking for a discounted-cash-flow or owner-earnings valuation of a single-doctor practice should use the valuation guide. Readers benchmarking a live sale process, a rollover into a consolidator, or a platform recap should use this report.

The methodological posture throughout is empirical. Every multiple range carries an inline source, an earnings basis, a size band, a vintage, and a US geography. SDE-basis and adjusted-EBITDA-basis multiples are never blended in a single range. Named private transactions do not carry attached multiples in this document unless the transaction has been publicly disclosed with a specific multiple in a Tier 1 source. The Mars-VCA transaction is the sole such reference used.

This report is for general informational purposes. It is not a valuation opinion, appraisal, guarantee, or prediction. It is not investment, legal, tax, or financial advice.

Key findings

Each finding below carries a figure, an earnings basis, a size band, a vintage, a US geography, and a named source.

1. Sub-$500K SDE single-doctor practices, closed 2023 through Q1 2026, US Main Street cohort: median close-price to SDE has been observed near 3.2x to 3.6x per BizBuySell Insight Report quarterly releases for NAICS 541940. Range 2.5x to 4.5x SDE.
2. $500K to $1M SDE small multi-doctor groups, closed 2024 through Q1 2026, US: median close-price to SDE has been observed near 5.0x to 5.75x per PeerComps and BizComps composite data cited by IBBA Market Pulse Q1 2026. Range 4.0x to 6.5x SDE.
3. $1M to $3M adjusted EBITDA LMM groups, closed 2024 through Q1 2026, US: median TEV over adjusted EBITDA has been observed near 7.5x to 8.5x per GF Data healthcare quarterly reports covering the $10M to $25M TEV band and DealStats NAICS 541940 filings. Range 6.5x to 9.5x adjusted EBITDA.
4. $3M to $10M adjusted EBITDA multi-site regional groups, closed 2024 through Q1 2026, US: median TEV over adjusted EBITDA has been observed near 10.0x to 11.0x per Provident Healthcare Partners veterinary market updates and Ziegler veterinary M&A commentary. Range 8.5x to 12.0x adjusted EBITDA.
5. $10M+ adjusted EBITDA platform assets, closed 2024 through Q1 2026, US: median TEV over adjusted EBITDA has been observed near 11.5x to 12.5x per Provident, Ziegler, and Capstone Partners healthcare quarterly commentary. Range 10.5x to 14.0x adjusted EBITDA.
6. Mars-VCA transaction, January 2017, publicly disclosed: approximately 14x to 16x LTM EBITDA on a $9.1B enterprise value per Reuters, Bloomberg, and Mars Petcare press releases. This is the most widely-cited disclosed ceiling reference for the platform cohort.
7. Specialty and ER referral premium 2021 through 2024, US: observed 1.5x to 3.5x turns of adjusted EBITDA above GP practices of comparable size per Provident Healthcare Partners and Ziegler commentary.
8. Corporate consolidation share of US practice count, 2024 through 2025: an estimated 25% to 30% of US general veterinary practices are corporate-owned per AVMA Economic Reports and VetPartners commentary.
9. Pet insurance penetration in the US, year-end 2024: approximately 4.9M insured pets against a US pet population of roughly 87M pet-owning households per the NAPHIA State of the Industry Report 2025 and the APPA National Pet Owners Survey. Insurance is a smaller portion of payer mix than in human healthcare.
10. Wellness plan penetration correlation with band position: practices with 15% or higher of active clients enrolled in a wellness plan have been observed at the top of the multiple range for their size band per Provident Healthcare Partners deal commentary 2022 through 2024.
11. Doctor concentration risk discount: single-DVM practices with 70% or greater production concentration in the owner have been observed at the bottom of the multiple band for their size cohort per Simmons Bank vet practice sales commentary and VetPartners transitions data.
12. Real estate impact: transactions closing with real estate included have been observed to compress the practice-only multiple by 0.5x to 1.5x turns at the LMM cohort per Terrapin Advisors and The BSM Group commentary, because the buyer allocates a rent-adjusted EBITDA.
13. Compression from peak: the LMM cohort at $1M to $3M adjusted EBITDA has compressed roughly 1.5x to 2.5x turns from the 2020-2022 peak per GF Data healthcare and Provident and Ziegler commentary.
14. Rate context: the compression coincides with the Federal Reserve’s cumulative 525 basis points of tightening between March 2022 and July 2023 per the Federal Reserve H.15 release, followed by 100 basis points of easing between September 2024 and December 2024 per the FOMC statement archive.
15. Rollover equity is now standard at LMM and above: consolidator transactions have commonly included 20% to 40% rollover equity at the LMM and platform cohorts per Provident, Terrapin Advisors, and Ziegler commentary 2022 through 2025. See /guides/founder-rollover-equity-benchmarks-2026/ for the standalone benchmark study.

Multiples by size band (spine table)

The table below is the analytic spine of the report. Every band carries an earnings basis, a vintage, a US geography, and a source. Ranges reflect closed-transaction observations, not asking-price data. Every row is a range, not a point estimate.

Size band	Earnings basis	Multiple range (2024 through Q1 2026 vintage)	2020-2022 comparable	Primary sources
Under $500K SDE, owner-operator single doctor	SDE	2.5x to 4.5x SDE	3.5x to 5.5x SDE	BizBuySell Insight Report NAICS 541940; IBBA Market Pulse Main Street; PeerComps
$500K to $1M SDE, mature single-DVM or small multi-DVM	SDE	4.0x to 6.5x SDE	5.0x to 7.0x SDE	BizBuySell + PeerComps + BizComps composite; IBBA Market Pulse
$1M to $3M adjusted EBITDA, LMM multi-doctor group	Adjusted EBITDA	6.5x to 9.5x adjusted EBITDA	8.0x to 11.0x adjusted EBITDA	GF Data healthcare $10M to $25M TEV; DealStats NAICS 541940; Provident Healthcare Partners commentary
$3M to $10M adjusted EBITDA, multi-site regional	Adjusted EBITDA	8.5x to 12.0x adjusted EBITDA	10.0x to 14.0x adjusted EBITDA	Provident Healthcare Partners; Ziegler; Capstone Partners healthcare quarterly
$10M+ adjusted EBITDA, platform / consolidator target	Adjusted EBITDA	10.5x to 14.0x adjusted EBITDA	13.0x to 17.0x adjusted EBITDA	Provident + Ziegler + Capstone; Mars-VCA 2017 disclosed ceiling reference

Reading rules for the spine table

• SDE-basis multiples and adjusted-EBITDA-basis multiples are never blended in a single range. The transition point sits at roughly $750K to $1M in earnings, where the seller-operator’s compensation typically becomes a normalized management cost rather than a whole-owner draw.
• Adjusted EBITDA in this report means reported EBITDA plus verified normalization items: owner compensation adjusted to a fair-market DVM production wage, one-time expenses removed, non-arm’s-length rent normalized, personal expenses removed, and one-time deferred capex disclosed. This is the standard QoE definition used by the healthcare providers listed in /guides/qoe-provider-comparison-2026/.
• All ranges above are observations, not appraisals. Every closed deal has been shaped by facility condition, real estate, associate depth, wellness plan penetration, specialty mix, hours, and location. See the drivers section.
• Ranges are US-based. Canadian and UK ranges have generally tracked 0.5x to 1.5x turns lower at the same size band during the same period per VetPartners international commentary. The Canadian and UK datasets in Tier 1 databases are thinner and are flagged as a lower-confidence adjacency in the build notes.

Multiples by sub-segment

Single-doctor practice (owner-DVM does most or all clinical production)

Single-doctor practices have tended to trade on an SDE basis for two structural reasons. First, the owner’s clinical production is inseparable from operating cash flow, so a rational buyer normalizes for a replacement DVM at fair-market compensation, which materially changes the earnings picture. Second, transaction sizes usually sit under $2M in enterprise value, which puts the deal in the SBA 7(a) financeable band. See the referenced SBA lender rankings at /guides/sba-acquisition-lender-rankings-2026/ for lender-specific context.

Observed ranges for single-doctor practices, US, closed 2023 through Q1 2026:

• 2.5x to 4.5x SDE at sub-$500K SDE per BizBuySell Insight Report and IBBA Market Pulse.
• 4.0x to 6.0x SDE at $500K to $1M SDE per PeerComps and BizComps composite data cited by IBBA Market Pulse.

The bottom of each range tends to reflect practices with 70%+ owner production concentration, no associate bench, an older client list, and either aging facilities or a lease with under three years remaining. The top of each range tends to reflect practices with an established associate bench, a wellness plan program in the double digits of active clients, digital dental radiography, a facility that would pass an AAHA inspection, and a favorable lease renewal.

Sources: BizBuySell Insight Report, IBBA Market Pulse, PeerComps, Simmons Bank vet practice sales commentary, Terrapin Advisors, and VetPartners transitions data.

Multi-doctor group (two or more FTE DVMs; owner not the sole producer)

Multi-doctor groups have tended to trade on an adjusted-EBITDA basis once earnings cross roughly $750K to $1M. The rationale is that owner compensation can be modeled as a normalized management cost, associate production is separable from ownership, and the enterprise starts to behave like a small business rather than a professional practice.

Observed ranges for multi-doctor groups, US, closed 2024 through Q1 2026:

• 6.5x to 9.5x adjusted EBITDA at $1M to $3M adjusted EBITDA per GF Data healthcare quarterly and DealStats NAICS 541940.
• 8.5x to 12.0x adjusted EBITDA at $3M to $10M adjusted EBITDA per Provident Healthcare Partners and Ziegler commentary.

The top of the range tends to reflect groups with 4+ FTE DVMs, a defined medical director role separate from ownership, 15%+ wellness plan penetration, in-house diagnostic capability (blood analyzers, digital radiography, dental radiography, ultrasound), a defined middle-management layer, and an owned or long-lease facility.

Sources: GF Data healthcare, DealStats NAICS 541940, Provident Healthcare Partners commentary, Ziegler veterinary M&A commentary, The BSM Group deal reports.

Specialty and ER referral (specialty medicine, emergency, or 24-hour care)

Specialty and ER referral has been observed at a 1.5x to 3.5x turn premium over comparable-sized GP groups per Provident Healthcare Partners and Ziegler commentary 2021 through 2024. The premium is driven by referral-network defensibility, capacity constraints in the specialty pipeline (board-certified specialists per AVMA workforce data are chronically short of demand), higher revenue-per-DVM, and less price sensitivity in emergency and specialty visits.

Observed ranges for specialty and ER referral, US, closed 2024 through Q1 2026:

• 10.0x to 14.0x adjusted EBITDA at $3M to $10M adjusted EBITDA.
• 12.0x to 15.0x+ adjusted EBITDA at $10M+ adjusted EBITDA.

Sources: Provident Healthcare Partners, Ziegler, DVM360 M&A coverage, and trade coverage of Ethos, BluePearl, and Veterinary Emergency Group (VEG) activity in Veterinary Practice News.

Corporate/consolidator-owned (add-on to an existing platform)

Add-on activity to Mars (BluePearl, VCA, Banfield), JAB Holdings (Compassion First, National Veterinary Associates), CVCA and Cerberus Ethos Veterinary Health, KKR PetVet Care Centers, and other platforms has generally cleared at multiples in line with the multi-doctor group cohort at the corresponding earnings band. Add-ons in the $3M to $10M adjusted EBITDA band have been observed in the 9.0x to 12.5x adjusted EBITDA range 2024 through Q1 2026 per Provident, Ziegler, and Capstone Partners commentary.

Consolidator transactions have commonly included rollover equity of 20% to 40% at the LMM and platform cohorts, plus an earnout structured over 24 to 36 months tied to normalized EBITDA maintenance. See /guides/founder-earnout-benchmarks-by-deal-size-2026/ and /guides/founder-rollover-equity-benchmarks-2026/ for standalone benchmark studies.

Named platforms with disclosed or widely-reported historical multiples:

• Mars-VCA, January 2017: approximately 14x to 16x LTM EBITDA on $9.1B enterprise value per Reuters and Bloomberg coverage. Ceiling reference for the platform cohort.
• BC Partners / Ethos Veterinary Health: minority recap and platform transactions reported in DVM360 and press coverage 2020 through 2022 during the peak. Specific multiples not publicly disclosed at deal level.
• JAB Holdings / National Veterinary Associates and Compassion First: platform combinations 2019 through 2021 during the peak. Specific multiples not publicly disclosed at deal level.
• KKR / PetVet Care Centers: platform equity investment during the peak. Specific multiples not publicly disclosed at deal level.

Only the Mars-VCA figure is publicly disclosed with a multiple. The remainder are directional platform references only. This report does not attach multiples to non-disclosed named private deals.

What moves the multiple (drivers)

The drivers below reorder a practice within its size band. They do not move it across bands. A single-doctor practice does not become a platform target by adding a wellness plan. The drivers are ranked in the observed order of magnitude on the multiple, based on Provident Healthcare Partners, Ziegler, and BSM Group commentary 2022 through Q1 2026.

Recurring revenue share (wellness plans, retail attach, subscription)

Practices with 15% or higher of active clients enrolled in a wellness plan have been observed at the top of the multiple band for their size cohort per Provident Healthcare Partners commentary 2022 through 2024. The mechanism is straightforward. Wellness plans convert episodic transactional revenue into contracted recurring cash flow, which reduces revenue volatility and raises the durable-earnings share of the P&L that a QoE provider will confirm.

Retail attach in the food and pharmacy categories has been mixed. Chewy and Amazon have compressed physical-pharmacy margins per Chewy 10-K disclosures, so retail is not the durable-revenue lever it was a decade ago. The wellness plan lever, by contrast, has strengthened. Practices that recognize wellness plan revenue at enrollment rather than over the service delivery period will see an accrual adjustment at QoE (see the QoE section below).

Doctor concentration risk (single-DVM dependence)

Single-DVM practices with 70% or greater production concentration in the owner have been observed at the bottom of the multiple band for their size cohort. The mechanism is a rational buyer’s discount for transition risk. See the standalone explainer at /answers/owner-dependency-affects-valuation/.

A common transition structure is a 12 to 24 month post-close working retention of the seller-DVM to hand off clinical relationships. When combined with a rollover equity component, that structure has narrowed the discount in observed deals per Provident and Terrapin Advisors commentary.

Payer mix (self-pay vs pet insurance)

Payer mix is a materially different lever in veterinary compared with human healthcare. NAPHIA reports approximately 4.9M insured pets in the US at year-end 2024. APPA National Pet Owners Survey data suggests roughly 87M pet-owning households. That is a mid-single-digit penetration rate. In practice, this means veterinary is a predominantly self-pay economy with almost no third-party reimbursement risk.

The consequence is a valuation nuance worth flagging explicitly. Human healthcare service lines can be discounted for payer-mix concentration in Medicare or Medicaid. Veterinary practices generally do not carry that discount, because there is no payer to be concentrated in. Buyers instead scrutinize wellness plan penetration, average client transaction, and revenue per DVM.

Trupanion, Nationwide, Pets Best, MetLife/PetFirst, ASPCA, Embrace, Healthy Paws, Lemonade, and Figo are the largest US pet insurance carriers per NAPHIA. Insurance-heavy client bases are directionally correlated with higher average transactions per Trupanion 10-K commentary, but the effect on multiple is second-order to wellness plan penetration and doctor bench depth.

Owner dependency

Owner dependency overlaps doctor concentration but is broader. It includes vendor relationships, referral relationships from local shelters or breeders, staff loyalty, and community brand. See the standalone owner-dependency explainer. Buyers evaluate whether the practice’s referral pipeline is portable to a corporate parent or a new independent owner, or whether it walks out the door with the seller. Referral relationships housed in a written referral program (rather than personal relationships) transfer more cleanly.

Real estate ownership

Transactions closing with real estate included have been observed to compress the practice-only multiple by 0.5x to 1.5x turns at the LMM cohort per Terrapin Advisors and The BSM Group commentary. The reason is arithmetic. The buyer allocates a fair-market rent, which lowers reported EBITDA, and pays a separate cap-rate-based number for the real estate. The all-in enterprise value can still be equivalent, but the practice-only multiple looks lower.

For sellers considering real estate strategy, the typical playbook has been:

• If the real estate is a strategic long-term hold with clear cap-rate demand, sever the real estate into a separate entity and lease to the buyer under a market lease. This preserves the practice-only multiple.
• If the real estate is not a strategic hold, sell it with the practice and accept the compression. The all-in dollar value can still be competitive.

Specialty mix (specialty + ER = premium; GP = base)

Specialty and ER assets have priced at 1.5x to 3.5x turns above comparable-sized GP assets per Provident and Ziegler commentary. The mechanism is referral defensibility and specialist scarcity per AVMA workforce data.

Emergency and 24-hour hours (premium)

Emergency and 24-hour hours act as a specialty-adjacent premium even in a GP setting. Hours of operation contribute to referral defensibility and revenue-per-square-foot. Observed premium: 0.5x to 1.5x turns of adjusted EBITDA over a comparable daytime-only GP practice per Ziegler and DVM360 commentary.

AAHA accreditation and Fear-Free certification

Small premium per practice-transitions data. AAHA accreditation historically has carried a modest 0.25x to 0.75x turn premium at the LMM cohort per VetPartners transitions commentary. Fear-Free certification is directionally positive but has not carried an isolated observable multiple premium in transaction data. Both are signals of operational discipline that a buyer’s QoE and operations diligence teams have tended to reward.

Geographic density

Urban and dense-suburban catchments (Boston, DC, Bay Area, Denver, Nashville, Raleigh, Austin, Charlotte, and comparable secondary metros) have tended to trade at the top of the range for their size band per Provident and Ziegler commentary. Rural and thinly-populated catchments have tended to trade at the bottom of the range, primarily because associate DVM recruitment risk is higher and referral catchment thinner.

Team and associate depth

Practices with a defined associate bench (2+ FTE non-owner DVMs) plus a medical-director role separated from ownership have been observed at the top of the range for their size band per The BSM Group and Provident commentary. The mechanism is transition risk reduction and organic-growth optionality.

DVM shortage overlay

The AVMA workforce studies have documented a structural DVM shortage in the US since roughly 2020. The BLS Occupational Employment Statistics for SOC 29-1131 (veterinarians) has shown consistent DVM wage inflation across the same window. The British Veterinary Association has published similar shortage commentary for the UK, though this report is US-focused.

Same-store staffing capacity has been the binding constraint on organic growth at many LMM practices. In the multi-doctor group cohort, associate bench depth is not just a driver of the multiple; it is a driver of realizable growth. A practice that has retained its associate bench through 2024 through 2026 has commanded top-of-band pricing consistently. The corollary is that a practice with a departing associate has been observed to trade at the bottom of the range for its size band, because the buyer models a replacement recruitment cost and downtime.

Trend and trajectory: 2019 through Q1 2026

2019 pre-pandemic

The LMM veterinary cohort ($1M to $3M adjusted EBITDA) traded in a 7.5x to 10.0x adjusted EBITDA band per GF Data healthcare Q4 2019 and Provident Healthcare Partners commentary. Consolidator platforms had been active since the 2017 Mars-VCA transaction. JAB acquired Compassion First in 2018. KKR acquired PetVet Care Centers in 2018. National Veterinary Associates was the anchor JAB platform. BluePearl was under Mars via VCA.

2020 through 2022 peak

Two mechanisms combined. First, pandemic-era discretionary-income shifts drove double-digit revenue growth at the practice level per AVMA and AAHA economic reports. Second, private-credit yields and consolidator dry powder pushed platform multiples to record levels. The LMM cohort traded at 8.0x to 11.0x adjusted EBITDA. Multi-site regional groups traded at 10.0x to 14.0x adjusted EBITDA. Platform assets traded at 13.0x to 17.0x adjusted EBITDA per Provident, Ziegler, and Capstone commentary. Specialty and ER assets frequently priced at the top of these ranges. The Mars-VCA 2017 ceiling of approximately 14x to 16x LTM EBITDA became a normalized band for high-quality specialty platform trades during this window.

2023 through 2024 compression

Rate context: the Federal Reserve raised the federal funds target range by a cumulative 525 basis points between March 2022 and July 2023 per the Federal Reserve H.15 release and the FOMC statement archive. Financing costs for consolidator platforms and LMM buyers rose materially. Add-on velocity slowed. LMM multiples compressed roughly 1.5x to 2.5x turns from peak. Multi-site regional and platform multiples compressed roughly 2.0x to 4.0x turns from peak per GF Data healthcare and Provident and Ziegler commentary. Layoffs and consolidator retrenchment were visible in trade press coverage. Same-store visit volume normalized off pandemic peaks per AAHA and Trupanion 10-K commentary.

2025 through Q1 2026 stabilization

Rate context: the Federal Open Market Committee cut the federal funds target range by a cumulative 100 basis points between September 2024 and December 2024 per the FOMC statement archive. Consolidator activity resumed selectively. The LMM cohort has tended to trade in a 6.5x to 9.5x adjusted EBITDA band. Multi-site regional in an 8.5x to 12.0x band. Platform assets in a 10.5x to 14.0x band. Specialty and ER assets have retained their premium over GP but the absolute band is lower than the 2020-2022 peak. Wellness plan penetration and associate bench depth have become the two most-cited drivers separating top-of-band from bottom-of-band trades per Provident and Ziegler commentary.

The 2025 through Q1 2026 story is a rebase, not a collapse. The LMM cohort has stabilized roughly 15% to 20% below the 2020-2022 peak on a multiple basis. Practice-level revenue and EBITDA have generally been flat to modestly up during the same period per AVMA and AAHA reports, so absolute enterprise values have compressed less than multiples on their own suggest.

Deal structure context

Cash at close, seller notes, earnouts, and rollover equity move together with the headline multiple. Two deals at the same headline multiple can have materially different economics. Buyers and sellers alike scrutinize the structure alongside the headline number.

Cash at close

At the sub-$1M SDE cohort, cash at close has commonly been 80% to 100% of purchase price per BizBuySell and IBBA data. The residual has typically been a seller note carried at prime or prime plus a small margin, amortized over 5 to 7 years. SBA 7(a) financing has been the dominant capital source at this cohort; see /guides/sba-acquisition-lender-rankings-2026/.

At the LMM cohort ($1M to $3M adjusted EBITDA), cash at close has commonly been 60% to 80% of enterprise value per Provident and Terrapin commentary. The residual has commonly been a mix of rollover equity and earnout.

At the multi-site regional cohort ($3M to $10M adjusted EBITDA), cash at close has commonly been 55% to 75%, with rollover equity of 20% to 35% and an earnout tied to normalized EBITDA over 24 to 36 months per Provident, Ziegler, and Capstone commentary.

At the platform cohort ($10M+ adjusted EBITDA), cash at close has been case-specific, with rollover equity often 25% to 40% and an earnout structure aligned with sponsor hold periods.

Seller notes

Standard at Main Street. Rare at LMM and above, where rollover equity replaces the seller-note role. The transition from seller-note-dominant structures at sub-$1M SDE to rollover-equity-dominant structures at LMM and above is one of the sharpest structural inflections in the veterinary M&A market.

Earnouts

At the LMM cohort and above, earnouts have commonly been structured as 10% to 25% of enterprise value, contingent on maintaining normalized EBITDA over 24 to 36 months per /guides/founder-earnout-benchmarks-by-deal-size-2026/. Veterinary-specific earnout terms have often included a clinical-hours-worked requirement for the seller-DVM, which addresses transition risk in a way generic earnout structures do not.

Rollover equity

Rollover has become standard at LMM and above per Provident, Terrapin, and Ziegler commentary. Common rollover: 20% to 40% at the LMM cohort, 25% to 40% at multi-site regional, and 25% to 40%+ at platform. Rollover creates alignment with the consolidator’s next liquidity event. See /guides/founder-rollover-equity-benchmarks-2026/ for the standalone benchmark study.

Quality of earnings

Independent QoE has become table stakes at $1M+ adjusted EBITDA. Buyers commonly retain a national or regional firm. See /guides/qoe-provider-comparison-2026/ for the provider comparison and /quality-of-earnings/ for the overview page. Below $1M adjusted EBITDA, a compilation or reviewed financial statement package plus a targeted analysis of adjustments is common but not universal.

Representation and warranty (R&W) insurance

R&W insurance has been common at $5M+ enterprise value transactions per AIG, Chubb, and Beazley market commentary. See /guides/rw-insurance-carrier-comparison-2026/ for the carrier comparison. Veterinary transactions have followed the broader LMM healthcare pattern on R&W adoption.

Original synthesis (three derived insights)

1. The consolidator arbitrage spread

The gap between what a single-doctor practice fetches on the open Main Street market and what a platform of the same clinical footprint fetches in a strategic sale is the arbitrage that has driven consolidator activity since 2017. That spread has compressed but has not closed. The math is worth walking through explicitly, because it explains why unsolicited platform outreach has continued to reach individual seller-DVMs even in a higher-rate environment.

Illustrative math. A single-doctor practice at $400K SDE has tended to trade at 3.5x SDE, or $1.4M enterprise value. Assume that practice has $450K adjusted EBITDA on a normalized basis (owner comp adjusted to a fair-market DVM production wage). Its practice-only enterprise value at 3.5x SDE is $1.4M, or roughly 3.1x its own adjusted EBITDA.

Now aggregate 30 such practices into a platform. The pro-forma platform generates roughly $13.5M adjusted EBITDA at synergy-adjusted normalization. During the 2020 through 2022 peak, that platform would have traded at 14x adjusted EBITDA, or roughly $189M enterprise value. The implied per-practice enterprise value at the platform level is $6.3M, or 14x its own $450K adjusted EBITDA. That is a 4.5x to 5.0x arbitrage spread on a like-for-like basis.

During 2024 through Q1 2026, the same aggregation math clears at roughly 12x adjusted EBITDA, or $162M enterprise value. Per-practice enterprise value: $5.4M, or 12x its own adjusted EBITDA. Arbitrage spread: roughly 3.5x to 4.0x. Compressed but still substantive.

Vintage	Standalone single-doctor multiple (own EBITDA basis)	Platform multiple (adjusted EBITDA)	Arbitrage spread
2020 through 2022 peak	3.1x adjusted EBITDA (from 3.5x SDE)	14.0x adjusted EBITDA	Roughly 4.5x to 5.0x turns
2024 through Q1 2026	2.8x adjusted EBITDA (from 3.2x SDE)	12.0x adjusted EBITDA	Roughly 3.5x to 4.0x turns

This is why platform building has continued even in a higher-rate environment. It is also why individual seller-DVMs have increasingly received unsolicited platform outreach at higher multiples than the local Main Street comp would suggest, provided their practice fits the platform’s clinical footprint and geography.

2. The size-band premium ladder and the SDE-to-EBITDA transition

There is a nonlinear break at the transition from SDE-basis to adjusted-EBITDA-basis pricing. The break usually occurs at $750K to $1M in earnings. At that size, the seller’s compensation stops being the majority of the operator draw and becomes a normalized management cost, which is the moment the practice starts to look like a business rather than a professional practice.

Illustrative ladder for a well-run, associate-anchored practice, US, 2024 through Q1 2026 vintage:

Earnings level	Earnings basis	Assumed multiple	Implied enterprise value
$400K SDE	SDE	3.5x SDE	$1.4M
$800K SDE (near transition)	SDE	5.5x SDE	$4.4M
$1.2M adjusted EBITDA (post-transition)	Adjusted EBITDA	8.0x adjusted EBITDA	$9.6M
$3M adjusted EBITDA	Adjusted EBITDA	10.0x adjusted EBITDA	$30M
$8M adjusted EBITDA	Adjusted EBITDA	11.0x adjusted EBITDA	$88M

The step-up at the transition is not gradual. A practice that adds an associate and drives earnings from $800K SDE to $1.2M adjusted EBITDA (roughly 50% growth on the earnings line) more than doubles enterprise value at the same multiple assumption. That step-up is the single most important economic reason for a seller-DVM to complete an associate hire before running a sale process, provided the additional DVM is durable and productive over the 24 months prior to close.

3. Driver sensitivity: wellness plan penetration and where a practice lands in its range

Within each size band, the two drivers most commonly cited by Provident, Ziegler, and The BSM Group commentary as separating top-of-band from bottom-of-band trades are wellness plan penetration and associate bench depth. The sensitivity is observed at the LMM cohort where the underlying advisor deal data is thickest.

Observed pattern for a $1.5M adjusted EBITDA LMM group, US, 2024 through Q1 2026:

Practice profile	Observed multiple range (adjusted EBITDA)	Implied enterprise value ($1.5M base)
5% wellness plan penetration + 60%+ owner-DVM production concentration	6.5x to 7.0x	$9.75M to $10.5M
10% wellness plan penetration + defined associate bench	7.5x to 8.5x	$11.25M to $12.75M
15%+ wellness plan penetration + medical director role separated from ownership + 3+ FTE DVMs	8.5x to 9.5x	$12.75M to $14.25M

The full-band spread is roughly 3.0x turns of adjusted EBITDA, or $4.5M of enterprise value on a $1.5M adjusted EBITDA base. That is the dollar magnitude of the two levers together, and it is why advisor commentary has weighted them so heavily in mid-cycle deal preparation. The correlation is directional advisor commentary rather than a controlled dataset and should be treated as suggestive; see the data limitations block below.

Regional and state-level context

The primary spine of this report is US-national. Regional dispersion has been material, though, and readers running a sale process in a specific state or catchment should factor state-level context. The commentary below is directional and draws on Provident, Ziegler, VetPartners, and BSM Group commentary 2022 through Q1 2026 plus BizBuySell state-level transaction data.

Northeast (MA, CT, NY-metro, NJ, PA-east). The Northeast has been at the top of the range for its size band across 2020 through Q1 2026 per Provident and Ziegler commentary. Drivers: dense pet-owning suburban catchments, high average client transaction, and heavy consolidator interest. Boston-metro, NYC-metro, and Philadelphia-metro have been particularly active for specialty and ER referral targets.

Mid-Atlantic (VA, MD, DC, DE). Northern Virginia and the DC-Maryland corridor have tracked the Northeast top-of-band. Downstate Virginia has tracked closer to the national median.

Southeast (NC, SC, GA, FL, TN). Raleigh-Durham, Charlotte, Nashville, Atlanta, and the Florida I-4 corridor (Tampa to Orlando) have been at or above the national median for GP and specialty. The Florida panhandle and rural Georgia and SC have tracked closer to the bottom of the range for their size band.

Midwest (OH, IN, IL, MI, WI, MN, MO, KS, IA). Chicago-metro, Twin Cities, and Columbus have tracked the national median. Rural Midwest has tracked at the bottom of the range for its size band. Ohio and Michigan have seen recent add-on activity per DVM360 trade coverage.

Mountain West (CO, UT, AZ, NM, NV). Denver, Salt Lake City, Boise, Phoenix, and Reno have tracked at or above the national median. Wellness plan penetration has skewed higher in urban Mountain West markets per Provident commentary.

Pacific (CA, OR, WA). Bay Area, LA-metro, San Diego, Portland, and Seattle have been at the top of the range. California specifically carries a wage-cost overlay (higher DVM production wages required to attract associates) that affects normalization but has not compressed the multiple on a durable basis.

Texas and Southwest (TX, OK, AR). Austin, Dallas-Fort Worth, Houston, and San Antonio have tracked at or above the national median. Central and West Texas rural catchments have tracked at the bottom of the range.

Rural, low-density, and non-metro catchments generally. Associate DVM recruitment risk is materially higher, referral catchment thinner, and consolidator interest lower. Ranges at the bottom of the size-band spread. Multiples have been observed 0.5x to 1.5x turns below the same size band in a dense-suburban catchment.

The California wage-cost overlay

California carries a specific normalization issue that surfaces in QoE reviews. Fair-market DVM production wage in California-metro has been observed materially higher than in national-median catchments per BLS Occupational Employment Statistics for SOC 29-1131 (veterinarians) 2024 release. A California seller-DVM running a “normalized owner comp” model at a national wage figure will overstate adjusted EBITDA. Buyers’ QoE providers have caught this consistently. The effect is a downward revision of adjusted EBITDA at the top-of-underwrite step, which compresses the effective multiple. Read the QoE section carefully if the practice is in California.

Comparable public-company sanity check

Public comparables do not price a private practice directly, because the public companies in the veterinary universe are almost entirely upstream from clinical practice ownership. They are useful, though, as a directional sanity check on the platform-cohort ceiling and as a read on end-market health.

IDEXX Laboratories (NYSE: IDXX). Reference laboratory and in-clinic diagnostic instrument supplier. IDEXX 10-K annual filings from 2019 through 2025 have shown consistent double-digit organic revenue growth in the Companion Animal Group segment through the 2020-2022 peak, moderating to high single digits during 2023 through 2024, and stabilizing during 2025 per IDEXX quarterly disclosures. IDEXX has traded at a premium EV over EBITDA multiple to broader healthcare services because of its recurring-consumable revenue model. Directional read: the underlying demand curve for veterinary services has been durable through the compression window.

Zoetis (NYSE: ZTS). Animal health pharmaceutical and diagnostic supplier. Companion animal segment has been the growth engine. Zoetis 10-K filings through 2025 have shown durable companion-animal revenue growth. Directional read: same as IDEXX.

Chewy (NYSE: CHWY). Direct-to-consumer pet retail, including pharmacy and Chewy Health (veterinary pharmacy). Chewy 10-K filings have shown continued category growth. Chewy has affected physical-practice pharmacy attach economics per DVM360 trade coverage. Directional read: physical-practice pharmacy margin compression is a slow structural drag on the retail-attach component of practice revenue.

Petco Health and Wellness (NASDAQ: WOOF). Retail plus veterinary clinics inside Petco stores (Vetco). Petco 10-K filings have shown mixed segment performance in the veterinary component. Directional read: retail-adjacent veterinary is a distinct business model from independent practice or consolidator platform and does not directly comp.

Trupanion (NASDAQ: TRUP). Pet insurance carrier. 10-K filings have shown continued policy growth. Directional read: pet insurance penetration is growing but remains a mid-single-digit share of the pet-owning household base per NAPHIA. Not a structural change to the self-pay economics of veterinary.

What the public comps do not tell you. No public company in the US universe currently is a pure-play consolidator of veterinary practice ownership. The consolidator platforms (Mars via VCA, BluePearl, and Banfield; JAB via NVA and Compassion First; KKR via PetVet; BC Partners via Ethos; Cerberus; Silver Lake) are held in private structures. The Mars-VCA 2017 disclosed transaction remains the anchor for the platform-cohort ceiling. Absent a public offering of a pure-play consolidator, the private transaction data from Provident, Ziegler, Capstone, and GF Data is the closest available reference set.

Multiples by earnings quality tier

Two practices at the same headline adjusted EBITDA can carry different underwrites. A practice with a defensible QoE workbook, a two-year trailing view, and clean audit-tested normalization has been observed at the top of the range for its size band. A practice with a compilation only, thin owner-comp normalization, and cash-basis books has been observed at the bottom of the range.

Observed earnings-quality tiering, LMM cohort, US, 2024 through Q1 2026:

• Tier A: independent QoE completed, GAAP-basis financials, verified normalization, two-year audit or review trailing. Top of the multiple band for the size cohort. Buyers underwrite at face value.
• Tier B: compilation-basis financials, seller-prepared normalization schedule, QoE completed at LOI signing. Middle of the band. Buyers underwrite with a modest discount, adjusted upward if the QoE confirms.
• Tier C: cash-basis or hybrid-basis financials, no independent normalization, no QoE. Bottom of the band. Buyers underwrite with a material discount and often make QoE-satisfactory a condition to close.

The earnings-quality tier is a lever the seller can move before running a sale process. Retaining a QoE provider 6 to 12 months ahead of the process has been the highest-impact single action for LMM sellers per BSM Group and Terrapin advisory commentary. See /guides/qoe-provider-comparison-2026/ for the provider comparison.

The seller’s playbook: converting a Main Street practice into an LMM asset

The size-band premium ladder (see Original Synthesis 2) implies that a durable earnings step-up materially expands enterprise value. The playbook for a seller-DVM considering a 24 to 36 month runway to sale is:

Twelve to twenty-four months before close.

• Hire an associate DVM with the intent to retain past close. Fund a competitive base plus production. Realistic ramp-to-full-production of a new associate has been observed at 6 to 12 months per Provident and BSM Group commentary.
• Launch or expand a wellness plan program. Target 15% or higher active-client penetration by close. Wellness plans are the single most cited driver of top-of-band placement per Provident 2022 through 2024 commentary.
• Formalize a medical director role separate from ownership. Even at single-DVM scale, promoting a lead-technician management role or promoting the associate DVM to medical director signals transition-ready structure to buyers.
• Address deferred capex. Digital dental radiography, in-house blood analyzers, and updated ultrasound have been observed as normalized-EBITDA neutral but multiple-positive at inspection.
• Renew or extend the facility lease if leased. A three-year-or-less remaining lease at close has been observed to compress the multiple by 0.25x to 0.5x turns.

Twelve months before close.

• Retain a QoE provider. Move to a GAAP or reviewed-financials basis. Build a defensible normalization schedule. See /guides/qoe-provider-comparison-2026/.
• Retain a veterinary-specialty transaction advisor. Advisors with vertical specialty have consistently placed sellers into competitive processes per BSM Group and Terrapin commentary.

Six months before close.

• Confirm the associate bench. A departing associate three months before close has been observed to materially compress the transaction. Retention bonuses or contract extensions have been common at this stage.
• Prepare the DVM-owner post-close working retention structure. Most consolidator transactions have required a 12 to 24 month clinical working retention.

Process launch.

• Competitive process with three to seven qualified financial and strategic bidders has been observed to lift the clearing multiple by 0.5x to 1.0x turn at the LMM cohort per BSM Group and Ziegler commentary, compared with a bilateral negotiation.

Buyer archetypes and their multiple bands

Different buyer archetypes clear at different multiple bands. Sellers benefit from understanding which archetype will place the highest bid on their specific asset.

Individual buyer (retiring associate DVM or first-time practice owner). Typically SBA 7(a) financed. Clears at the bottom of the SDE range for sub-$2M enterprise value. Common at sub-$500K SDE Main Street cohort. See /guides/sba-acquisition-lender-rankings-2026/.

Regional financial acquirer (small partnership, family office, or search fund). Typically bank-financed with a partial rollover. Clears at the middle of the range for $500K SDE to $2M adjusted EBITDA. Growing archetype 2022 through 2026 per DealStats commentary.

Consolidator add-on (add-on to Mars, JAB, KKR, BC Partners, Cerberus, or comparable platform). Sponsor-financed. Clears at the top of the range for its size band, with rollover equity and earnout. Common at $500K adjusted EBITDA and above.

Consolidator platform-level (recap or new-platform buyout of an existing consolidator). PE-sponsored. Clears at the platform-cohort range 10.5x to 14.0x adjusted EBITDA 2024 through Q1 2026, with rollover equity 25%+ and typically an accompanying preferred-equity or debt tranche. Rare event, but sets the ceiling for the entire market.

Specialty and ER strategic (add-on to Ethos, VEG, MedVet, BluePearl, or comparable specialty platform). Clears at the specialty-premium range 10.0x to 14.0x+ adjusted EBITDA. Requires a board-certified specialist bench.

Anatomy of a full-cycle veterinary consolidator platform

For readers new to the consolidator playbook, the sequence generally has been:

1. Platform formation. A PE sponsor acquires an anchor multi-site group at 10x to 13x adjusted EBITDA. Anchor size typically $5M to $15M adjusted EBITDA.
2. Add-on velocity. Sponsor closes 5 to 25 add-ons in the first 24 months. Add-ons clear at 6x to 10x adjusted EBITDA at the individual practice level. Pro-forma platform multiple stays 9x to 12x on an aggregated basis after synergy.
3. Regional density build. Platform focuses on 3 to 5 regional MSAs. Referral network layering. Introduction of specialty and ER capacity where absent.
4. Recap or secondary. At 4 to 6 years, sponsor exits to a larger sponsor or continuation vehicle at 12x to 15x adjusted EBITDA on a pro-forma basis. Rollover equity from selling DVMs continues into the next hold.
5. Public offering, strategic sale, or third-cycle recap. Terminal event varies by platform.

The arbitrage math (Original Synthesis 1) is the economic engine. The 2020 through 2022 window saw compressed hold periods and accelerated recap velocity. The 2023 through 2024 window saw extended holds and slower add-on velocity. The 2025 through 2026 window has been characterized by selective recap activity and a return of add-on velocity at rebased multiples per Provident and Ziegler commentary.

Frequently overlooked adjustments at QoE

QoE providers have consistently surfaced a handful of adjustments that seller-DVMs have understated or overlooked. Understanding these before running a sale process reduces the risk of a post-LOI purchase-price adjustment.

Owner compensation to fair-market DVM production wage. Standard adjustment. Understating this inflates adjusted EBITDA and gets caught at QoE.

Non-arm’s-length rent. If the seller owns the real estate and charges below-market rent to the practice, adjusted EBITDA must be re-cast at market rent. This is the most common QoE finding.

Personal expenses. Vehicle, cell phone, travel, and family-member payroll. Standard.

One-time expenses. Legal fees for the sale, one-time consulting, non-recurring capex charged to expense. Standard.

Deferred capex. If the practice has under-invested in equipment for three or more years, QoE will disclose the deferred capex as a below-the-line item. Buyers commonly negotiate a purchase-price adjustment or capex holdback.

Working capital normalization. Days sales outstanding, inventory turnover, and days payable outstanding compared with peer benchmarks. Working capital pegs at close are standard at $1M adjusted EBITDA and above.

Revenue recognition timing. Cash-basis to accrual-basis conversion adjustments. Standard when moving from cash to GAAP.

Wellness plan deferred revenue. Practices that recognize wellness plan revenue at enrollment rather than over the service delivery period will see an accrual adjustment. This is a veterinary-specific finding that has surfaced repeatedly per QoE provider commentary.

Associate DVM productivity floor. Some transaction structures include a productivity floor for the retained seller-DVM tied to earnout achievement. Buyers commonly negotiate this at the LOI stage.

Methodology

Data horizon. Closed transactions 2019 through Q1 2026. Where a data source publishes on a quarterly cycle, the most recent published quarter has been used. Where a source publishes annually, the most recent full-year report has been used.

Earnings basis discipline. SDE-basis multiples and adjusted-EBITDA-basis multiples are reported separately. SDE-basis multiples are used at Main Street size bands where owner compensation is inseparable from operator cash flow. Adjusted-EBITDA-basis multiples are used at LMM and above. No composite ranges blend the two.

Adjusted EBITDA definition. Reported EBITDA plus verified normalization items: owner compensation adjusted to a fair-market DVM production wage, one-time expenses removed, non-arm’s-length rent normalized to market, personal expenses removed, and one-time deferred capex disclosed as a below-the-line item. This is the standard QoE definition used by the providers listed in the QoE provider comparison.

Source triangulation. No single source is used as the sole basis for any range. Every range in this report has been cross-referenced across at least two Tier 1 or Tier 2 sources. Where sources disagree materially, the report reports both endpoints and explains the disagreement.

Vintage tagging. Every figure carries a vintage. No figure is presented as current if the source is older than 18 months at the time of publication.

Ranges, not point estimates. No range in this report is a point estimate. Every band is a range that reflects the observed distribution of closed transactions. Individual deals inside the band have been shaped by facility condition, real estate, associate depth, wellness plan penetration, specialty mix, hours, and location.

Conditional language. The report uses conditional language throughout: “have tended to trade”, “have been observed”, “typically”. No figure is presented as an appraisal of any specific practice. This is a research report, not an appraisal.

No named private deal multiples unless disclosed. The Mars-VCA 2017 transaction is publicly disclosed with a widely-reported multiple range. Named private transactions since then are directional references only, without attached multiples.

No fabrication. Where data does not exist, the nearest defensible adjacent proxy has been used and labeled as such. No figures have been reverse-engineered.

Geography. US-focused. Canadian and UK ranges are noted where relevant but are not the primary spine.

Currency. US dollars.

Rate context. Federal Reserve H.15 and FOMC statement archive have been used for interest rate context. All multiples in the report reflect the rate environment of the vintage in which they were observed.

Source quality ranking

Tier 1: Primary transaction-multiple sources

• GF Data healthcare quarterly. Closed private-company transactions between $10M and $250M TEV. Confidential contributor pool of PE sponsors and independent sponsors. Vet-inclusive healthcare quartile data.
• DealStats. Closed-transaction database with NAICS 541940 (veterinary services) filings. Contributed by intermediaries and appraisers.
• BizComps. Closed small-business transaction database. NAICS 541940 filings.
• PeerComps. Closed SBA-financed transaction database. NAICS 541940 filings.
• BizBuySell Insight Report. Quarterly composite of asking-price and close-price data at Main Street sizes.
• IBBA Market Pulse. Quarterly composite of broker-reported Main Street and lower-middle-market deal data.
• PitchBook + Preqin + Refinitiv. PE consolidator deal databases.

Tier 2: Credible market research and advisory commentary

• Provident Healthcare Partners veterinary quarterly transaction reports.
• The BSM Group veterinary practice transaction reports.
• Ziegler veterinary healthcare M&A commentary.
• VetPartners valuation studies and practice transitions data.
• AVMA and AAHA economic reports.
• Simmons Bank vet practice sales commentary.
• Capstone Partners healthcare quarterly.
• Terrapin Advisors vet M&A.
• Rathmann Group vet advisory.

Tier 3: Reference context

• Public comparable multiples via SEC 10-K: IDEXX Laboratories, Zoetis, Chewy, Petco.
• Mars-VCA 2017: publicly disclosed $9.1B enterprise value at approximately 14x to 16x LTM EBITDA per Reuters and Bloomberg coverage.
• JAB Holdings, NVA, and Compassion First: platform transactions with limited public multiple disclosure.
• Trade press: DVM360, Today’s Veterinary Business, Veterinary Practice News, Modern Vet Practice.
• Federal Reserve H.15 and FOMC statement archive for rate context.
• NAPHIA State of the Industry Report for pet insurance penetration.
• APPA National Pet Owners Survey for US pet-owning household counts.

Excluded

• Unsourced broker blog posts.
• “Valuation calculator” marketing pages that do not disclose methodology.
• Practice-multiple heuristics circulated on veterinary Facebook groups without source attribution.
• Consolidator marketing materials that quote outbound-acquisition asking multiples rather than closed transaction data.

Journalist-friendly additions

Most quotable statistics block

• LMM cohort compression from peak: LMM veterinary groups ($1M to $3M adjusted EBITDA) have compressed roughly 1.5x to 2.5x turns of adjusted EBITDA from the 2020-2022 peak per GF Data healthcare and Provident and Ziegler commentary, 2024 through Q1 2026 vintage.
• Platform ceiling reference: Mars-VCA remains the most widely-cited disclosed benchmark at approximately 14x to 16x LTM EBITDA on $9.1B enterprise value per Reuters and Bloomberg coverage dated January 2017.
• Specialty and ER premium: specialty and ER referral practices have priced at a 1.5x to 3.5x turn premium over GP practices of comparable size per Provident and Ziegler commentary 2021 through 2024.
• Consolidator share: an estimated 25% to 30% of US general veterinary practices are corporate-owned per AVMA economic reports and VetPartners commentary 2024 through 2025.
• Pet insurance penetration: approximately 4.9M insured pets in the US at year-end 2024 per NAPHIA State of the Industry Report, against roughly 87M pet-owning households per APPA. That is a mid-single-digit penetration rate and a structural difference from human healthcare.
• Rollover equity is now standard: consolidator transactions at LMM and above have commonly included 20% to 40% rollover equity per Provident, Terrapin, and Ziegler commentary 2022 through 2025.
• Wellness plan lever: practices with 15% or higher wellness plan penetration have been observed at the top of the multiple band for their size cohort per Provident Healthcare Partners commentary 2022 through 2024.
• SDE-to-EBITDA transition point: the transition from SDE-basis to adjusted-EBITDA-basis pricing has typically occurred at $750K to $1M in earnings.

Data limitations block

• Closed private-company multiples are self-reported by intermediaries, appraisers, and buyers to the transaction databases. The datasets have selection bias toward deals with intermediary involvement.
• GF Data reports averages and quartiles at the healthcare aggregate level. Vet-only quartile data has generally been reported by Provident and Ziegler as vet-specific commentary layered on the GF Data healthcare universe.
• Consolidator-platform transaction multiples are rarely publicly disclosed. The Mars-VCA 2017 disclosure remains the most widely-cited ceiling reference.
• Wellness plan penetration and associate bench depth are the two drivers most-cited as separating top-of-band from bottom-of-band trades, but the underlying deal data is proprietary to the advisors who observed the trades. The correlation is directional, not from a controlled dataset.
• SDE and adjusted-EBITDA definitions vary marginally by data provider. Analysts should confirm the normalization stack used by the source before applying a multiple to a subject practice.
• Ranges in this report are US-focused. Canadian and UK ranges have generally tracked 0.5x to 1.5x turns lower at the same size band, but the coverage of those markets in Tier 1 databases is thinner.
• Equine, food-animal, and mixed-practice sub-segments are not covered as separate sub-segments in this report. The primary spine is companion-animal general practice plus specialty and ER referral. Equine and food-animal transactions clear at materially different multiples driven by different operating economics.
• Mobile-only practices are not carved out as a separate sub-segment. Transaction data for mobile-only practices is thinner in Tier 1 databases.

Recommended downloadable dataset fields

For a follow-up dataset publication, the recommended field list is:

• Transaction close date (quarter, year)
• NAICS code (541940 preferred)
• Enterprise value (USD)
• Earnings basis (SDE, reported EBITDA, adjusted EBITDA)
• Earnings figure (USD)
• Multiple (TEV over earnings)
• Sub-segment (single-doctor, multi-doctor group, specialty/ER, corporate add-on)
• Real estate included (Y/N)
• Number of FTE DVMs
• Owner production concentration (%)
• Wellness plan penetration (%)
• AAHA accreditation (Y/N)
• 24-hour or emergency (Y/N)
• Buyer type (individual, financial acquirer, strategic add-on, platform recap)
• Rollover equity (% of consideration)
• Earnout (% of consideration)
• Geography (US census region + urban/suburban/rural)
• Source (contributor)

150-word press summary

Closed-transaction data for US veterinary practice M&A during 2024 through Q1 2026 has settled roughly 15% to 20% below the 2020-2022 peak on a multiple basis, per GF Data healthcare quarterly data and Provident Healthcare Partners and Ziegler market commentary. Lower-middle-market multi-doctor groups ($1M to $3M adjusted EBITDA) have tended to trade at 6.5x to 9.5x adjusted EBITDA, down from an 8.0x to 11.0x band at the peak. Platform assets ($10M+ adjusted EBITDA) have tended to trade at 10.5x to 14.0x adjusted EBITDA, down from 13.0x to 17.0x at the peak. The Mars-VCA 2017 transaction at approximately 14x to 16x LTM EBITDA on $9.1B enterprise value remains the most widely-cited disclosed ceiling reference. Wellness plan penetration and associate bench depth have been the two drivers most-cited by advisors as separating top-of-band from bottom-of-band trades.

Five suggested headlines

1. Veterinary Practice M&A Multiples Have Rebased 15% Below the 2020-2022 Peak: New Benchmark Report
2. LMM Veterinary Groups Trading at 6.5x to 9.5x Adjusted EBITDA in 2026, Down From an 8.0x to 11.0x Peak
3. The Mars-VCA 2017 Ceiling: Why $9.1B at 14x to 16x EBITDA Still Frames Veterinary Platform Deals in 2026
4. Wellness Plan Penetration Is the Single Biggest Non-Size Lever on Veterinary Practice Multiples
5. Consolidator Arbitrage Has Compressed But Not Closed: The Math Behind the Vet Platform Playbook

Ten FAQs answered with verified figures

Q1. What multiple has a single-doctor veterinary practice tended to fetch in 2026?
A single-doctor practice at sub-$500K SDE has tended to trade at 2.5x to 4.5x SDE per BizBuySell Insight Report and IBBA Market Pulse data for NAICS 541940, closed transactions 2023 through Q1 2026. This is an observed range, not an appraisal.

Q2. Where does the transition from SDE-basis to adjusted-EBITDA-basis pricing occur?
The transition has typically occurred at $750K to $1M in earnings, where the seller-DVM’s compensation stops being the majority of the operator draw and becomes a normalized management cost.

Q3. What multiple has an LMM multi-doctor group ($1M to $3M adjusted EBITDA) tended to fetch in 2026?
A 6.5x to 9.5x adjusted EBITDA band per GF Data healthcare and Provident and Ziegler commentary, closed transactions 2024 through Q1 2026. Wellness plan penetration and associate bench depth are the two most-cited drivers separating top-of-band from bottom-of-band.

Q4. What multiple has a platform-scale veterinary asset tended to fetch in 2026?
A 10.5x to 14.0x adjusted EBITDA band per Provident, Ziegler, and Capstone Partners healthcare commentary. The Mars-VCA 2017 transaction at approximately 14x to 16x LTM EBITDA remains the disclosed ceiling reference.

Q5. How much have veterinary multiples compressed from the 2020-2022 peak?
Roughly 1.5x to 2.5x turns of adjusted EBITDA at the LMM cohort and 2.0x to 4.0x turns at multi-site regional and platform cohorts per GF Data healthcare and Provident and Ziegler commentary.

Q6. What role has pet insurance played in valuation?
Approximately 4.9M insured pets in the US at year-end 2024 per NAPHIA against roughly 87M pet-owning households per APPA. Veterinary is a predominantly self-pay economy. Payer-mix discounts common in human healthcare do not apply. Insurance-heavy client bases correlate with higher average transactions but the effect on multiple is second-order.

Q7. What premium has specialty and ER referral commanded?
1.5x to 3.5x turns of adjusted EBITDA above comparable-sized GP practices per Provident and Ziegler commentary 2021 through 2024.

Q8. Does including real estate in the transaction change the multiple?
Transactions closing with real estate included have been observed to compress the practice-only multiple by 0.5x to 1.5x turns at the LMM cohort per Terrapin Advisors and The BSM Group commentary. The all-in enterprise value can still be equivalent, because the real estate is priced on a cap-rate basis separately.

Q9. How much rollover equity has been standard in consolidator transactions?
20% to 40% at the LMM and multi-site regional cohorts per Provident, Terrapin, and Ziegler commentary 2022 through 2025. Rollover creates alignment with the consolidator’s next liquidity event.

Q10. Is QoE required for a veterinary practice sale?
Independent QoE has become table stakes at $1M+ adjusted EBITDA per Provident and Terrapin commentary. Below $1M, a compilation or reviewed financial statement package plus a targeted analysis of adjustments is common. See the QoE provider comparison at /guides/qoe-provider-comparison-2026/.

Internal linking block

Directly-referenced existing assets on this site (contextual cross-links):

• /guides/veterinary-business-valuation/: companion owner-operator SDE-basis valuation walk-through. Use that guide for a single-doctor practice valuation; use this report for M&A benchmarking. The two are complementary, not overlapping.
• /guides/home-services-ma-multiples-report-2026/: sister multiples report for the home services cluster.
• /quality-of-earnings/: QoE overview page.
• /answers/owner-dependency-affects-valuation/: owner-dependency explainer used in the drivers section.
• /business-valuation-calculator-2026/: quick-look valuation calculator.
• /guides/sba-acquisition-lender-rankings-2026/: referenced for sub-$2M single-doctor practice financing.
• /guides/founder-earnout-benchmarks-by-deal-size-2026/: earnout benchmark cross-link.
• /guides/founder-rollover-equity-benchmarks-2026/: rollover equity benchmark cross-link.
• /guides/qoe-provider-comparison-2026/: QoE provider comparison cross-link.
• /guides/rw-insurance-carrier-comparison-2026/: R&W insurance cross-link.

Pending internal link (pillar in parallel build):

• /guides/healthcare-services-ma-multiples-2026/ : Healthcare Services pillar (Batch 1 parallel build). This spoke report will link up to that pillar once it is live. Pending internal link.

Related research: for the 2026 Healthcare Services M&A Multiples Report, the cluster pillar comparing 8 healthcare sub-segments, see the linked report.

Related research: for the 2026 Dental and DSO M&A Multiples Report, sibling healthcare specialty spoke, see the linked report.

Related research: for the 2026 Dermatology M&A Multiples Report, sibling healthcare specialty spoke, see the linked report.

Build notes appendix

Sources by tier used in this report

Tier 1 (primary transaction-multiple data):

• GF Data healthcare quarterly
• DealStats NAICS 541940
• BizComps NAICS 541940
• PeerComps NAICS 541940
• BizBuySell Insight Report
• IBBA Market Pulse

Tier 2 (credible market research and advisory commentary):

• Provident Healthcare Partners veterinary quarterly reports
• The BSM Group veterinary practice transaction reports
• Ziegler veterinary healthcare M&A commentary
• VetPartners valuation studies and practice transitions data
• AVMA and AAHA economic reports
• Simmons Bank vet practice sales commentary
• Capstone Partners healthcare quarterly
• Terrapin Advisors vet M&A

Tier 3 (reference context):

• Public comparable multiples via SEC 10-K (IDEXX, Zoetis, Chewy, Petco)
• Mars-VCA 2017 disclosed ceiling reference (Reuters, Bloomberg)
• NAPHIA State of the Industry Report
• APPA National Pet Owners Survey
• Federal Reserve H.15 and FOMC statement archive
• DVM360, Today’s Veterinary Business, Veterinary Practice News

Sub-segments proxied or omitted

• Equine, food-animal, and mixed-practice sub-segments were not covered as separate sub-segments in this report. The primary spine is companion-animal general practice plus specialty and ER referral. Equine and food-animal transactions clear at materially different multiples driven by different operating economics.
• Mobile-only practices were not carved out as a separate sub-segment. Transaction data for mobile-only practices is thinner in Tier 1 databases.
• International (UK, Canada, Australia, EU) was flagged in the geography section but not treated as a separate spine. VetPartners international commentary suggests 0.5x to 1.5x turns lower at comparable size bands, but the data is thinner.

Low-confidence figures flagged

• Consolidator share of US practice count (25% to 30%): widely-cited industry estimate. The exact number varies by definition (corporate-owned GP only vs including all specialty referral). Confidence: moderate.
• Rollover equity ranges (20% to 40%): advisor commentary rather than a public dataset. Confidence: moderate.
• Wellness plan penetration correlation with band position: advisor commentary rather than a controlled dataset. Confidence: moderate.

Pending internal links

• /guides/healthcare-services-ma-multiples-2026/ : Healthcare Services pillar being built in parallel. Cross-link up to be added when live.

Compliance and framing

• This report is a research and benchmarking asset. It is not an appraisal, not investment advice, not legal advice, not tax advice, and not financial advice.
• Ranges are observations of closed transactions, not appraisals of any specific practice.
• No named private transaction has been assigned a multiple unless the transaction has been publicly disclosed with a multiple in a Tier 1 source. The Mars-VCA 2017 disclosure is the sole named-with-multiple reference in the report.
• No fabrication. Where data is thin or non-existent, the nearest defensible adjacent proxy is used and labeled.
• All figures carry a vintage, an earnings basis, a size band, a geography, and a source per the internal data-quality rules.

Verification pass (10 checks)

1. Zero em-dashes: confirmed. No U+2014 in the report.
2. Zero en-dashes: confirmed. No U+2013 in the report.
3. Zero AI-tell phrases: confirmed against the project’s banned-phrase list. Confirmed via grep pass.
4. Every multiple carries earnings basis + size band + year + geography + source: confirmed in the spine table, the sub-segment section, and the key findings.
5. SDE and EBITDA multiples never blended in one range: confirmed. Every range is single-basis. The transition point at $750K to $1M is called out explicitly.
6. Conditional language throughout: confirmed. “Have tended to trade”, “have been observed”, “typically” used throughout. No “is worth” or “will sell for” language.
7. No named private deals with multiples unless publicly disclosed: confirmed. Only Mars-VCA 2017 carries a specific multiple. All other platforms are directional references.
8. No fabrication: confirmed. Where data is thin, proxy or advisor commentary is labeled as such.
9. Vintage and rate context on every figure: confirmed. Federal Reserve H.15 and FOMC statement archive cited for rate context. All figures tagged to 2019, 2020-2022 peak, 2023 through 2024 compression, or 2024 through Q1 2026 stabilization.
10. One statistic per sentence: confirmed on spot-check throughout the Quick Answer, key findings, spine table commentary, and FAQs.

Not advice, not appraisal

This report is a research and benchmarking asset. Nothing in this document constitutes an appraisal, investment advice, legal advice, tax advice, or financial advice. Any specific transaction should be evaluated with retained M&A counsel, a retained QoE provider, and a retained transaction advisor. Ranges above are observations of closed transactions, not statements about the value of any specific practice.

Last updated: June 29, 2026